Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
Stockhead on MSN6 天
Rare opportunities – ASX health stocks tackling unmet medical needs
Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally. ... Read ...
Pharmabiz3 天
US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy ...
The US FDA fast track designation is intended to accelerate the development and review process for therapies addressing serious health conditions and unmet medical needs and offers hope for faster ...
manilatimes12 天
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral ...
LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic ...
Taiwan News12 天
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral ...
06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet ...
Adelaide Now6 天
Rare opportunities – ASX health stocks tackling unmet medical needs
"The FDA is also showing a willingness to look ... a compelling opportunity to bring breakthrough therapies for unmet medical needs to market. Here are some biotechs leading the charge in rare ...
Nasdaq12 天
Lipella Pharmaceuticals Announces FDA Approval for Expanded Access Program for LP-310 in ...
The condition impacts approximately 6 million Americans and currently has no FDA-approved therapies. Expanded Access Programs allow patients who have unmet medical needs with serious or life ...